Cocrystal Pharma, Inc. income statement

In fiscal 2020, Cocrystal Pharma, Inc. reported revenue of $2.0m, down 69.3% on the year before, operating income of −$9.6m (a -476.0% margin) and net income of −$9.6m, or −$2.04 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cocrystal Pharma, Inc.: income statement, annual
Fiscal year	2011Dec 2011	2019Dec 2019	2020Dec 2020
Revenue	13	7	2
Gross profit	3	—	—
Research and development	0	4	6
Selling and marketing	1	—	—
General and administrative	5	5	6
Operating income	−4	−48	−10
Interest expense	−1	0	0
Net interest income	—	−0	—
Income before tax	−5	−48	−10
Income tax	0	—	—
Net income	−5	−48	−10
Diluted EPS	−$1.32	−$18.12	−$2.04
Diluted shares (average)	—	—	5m
EBITDA	−3	−48	−9

US$ millions unless shown otherwise. Fiscal quarters.

Cocrystal Pharma, Inc.: income statement, quarterly
Quarter	2019 Q3Sept 2019	2019 Q4Dec 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	0	0	1	0	1	0	0
Research and development	1	1	1	2	2	1	1	2
General and administrative	1	1	1	2	1	1	1	1
Operating income	−2	−48	−2	−3	−3	−1	−2	−3
Interest expense	0	0	0	0	0	0	−0	−0
Net interest income	−0	−0	−0	—	—	—	—	—
Income before tax	−2	−48	—	—	—	—	—	—
Income tax	—	—	—	—	—	—	0	0
Net income	−2	−48	−2	−3	−3	−1	−2	−3
Diluted EPS	−$0.06	−$18.00	−$0.05	−$0.07	−$0.05	−$0.12	−$0.17	−$0.23
EBITDA	−2	−48	−2	−3	−3	−1	−2	−3

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cocrystal Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cocrystal Pharma, Inc.